Advertisement

Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study

Published:November 28, 2018DOI:https://doi.org/10.1016/j.clcc.2018.11.005

      Abstract

      Background

      Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and effectiveness of targeted therapies in first-line mCRC treatment according to age.

      Patients and Methods

      Two field cohorts of patients initiating bevacizumab or cetuximab for first-line mCRC were pooled. Patients characteristics, use, and safety were compared between younger and elderly patients (<75 vs. ≥75 years). Two-year overall survival (OS) and progression-free survival (PFS) were estimated in both age groups using the Kaplan–Meier method adjusted on factors associated with death or progression identified with Cox multivariate modeling.

      Results

      Eight hundred patients (n = 411, 51.4% bevacizumab) were included: 498 (62.3%) male, median age 64 years, 118 (14.8%) Eastern Cooperative Oncology Group performance status (ECOG-PS) ≥2. Elderly patients (n = 126, 15.8%) were more often treated with 5-fluorouracil alone than younger. Severe adverse events were equivalent across age groups. ECOG-PS ≥1, abnormal hemoglobin, and abnormal alkaline phosphatases were associated with a higher risk of death; OS adjusted on these factors was similar between elderly and younger patients. ECOG-PS ≥1, lung metastases, abnormal hemoglobin, and abnormal creatinine clearance were associated with a higher risk of progression or death; PFS adjusted on these factors was similar across groups.

      Conclusion

      Despite treatment adaptations, elderly patients could benefit from targeted therapies as younger without safety warning.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Fedewa S.A.
        • et al.
        Colorectal cancer statistics, 2017.
        CA Cancer J Clin. 2017; 67: 177-193
        • National Cancer Institute
        Surveillance, Epidemiology, and End Results. SEER Cancer Statistics Review (CSR) 1975-2014.
        (Available at:)
        • Del Rio M.
        • Mollevi C.
        • Vezzio-Vie N.
        • et al.
        Specific extracellular matrix remodeling signature of colon hepatic metastases.
        PLoS One. 2013; 8: e74599
        • Papamichael D.
        • Audisio R.
        • Glimelius B.
        • et al.
        Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.
        Ann Oncol. 2015; 26: 463-476
        • Van Cutsem E.
        • Cervantes A.
        • Adam R.
        • et al.
        ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
        Ann Oncol. 2016; 27: 1386-1422
        • Gouverneur A.
        • Salvo F.
        • Berdaï D.
        • et al.
        Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: a systematic review.
        J Geriatr Oncol. 2018; 9: 15-23
        • Fourrier-Réglat A.
        • Smith D.
        • Rouyer M.
        • et al.
        Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort.
        Target Oncol. 2014; 9: 311-319
        • Rouyer M.
        • François E.
        • Cunha A.S.
        • et al.
        Effectiveness of cetuximab as first-line therapy for patients with wild-type KRAS and unresectable metastatic colorectal cancer in real-life practice: results of the EREBUS Cohort.
        Clin Colorectal Cancer. 2018; 17: 129-139
      1. Common Terminology Criteria for Adverse Events, v.0.
        (Available at:)
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • et al.
        New guidelines to evaluate the response to treatment in solid tumors.
        J Natl Cancer Inst. 2000; 92: 205-216
        • Rubin D.B.
        Multiple imputation after 18+ years.
        J Am Stat Assoc. 1996; 91: 473-489
        • Kozloff M.
        • Berlin J.
        • Flynn P.
        • et al.
        Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study.
        Oncology. 2010; 78: 329-339
        • Jehn C.F.
        • Böning L.
        • Kröning H.
        • et al.
        Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer.
        Eur J Cancer. 2014; 50: 1269-1275
        • Gouverneur A.
        • Claraz P.
        • Rousset M.
        • et al.
        Comparative safety of targeted therapies for metastatic colorectal cancer between elderly and younger patients: a study using the International Pharmacovigilance Database.
        Target Oncol. 2017; 12: 805-814
        • Jehn C.
        • Böning L.
        • Kröning H.
        • et al.
        Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer.
        Br J Cancer. 2012; 106: 274-278
        • Keikes L.
        • van Oijen M.G.H.
        • Lemmens V.E.P.P.
        • et al.
        Evaluation of guideline adherence in colorectal cancer treatment in The Netherlands: a survey among medical oncologists by the Dutch Colorectal Cancer Group.
        Clin Colorectal Cancer. 2018; 17: 58-64
        • Parakh S.
        • Wong H.
        • Rai R.
        • et al.
        Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia.
        J Geriatr Oncol. 2015; 6: 387-394
        • Saliba D.
        • Elliott M.
        • Rubenstein L.Z.
        • et al.
        The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community.
        J Am Geriatr Soc. 2001; 49: 1691-1699
        • Soubeyran P.
        • Bellera C.
        • Goyard J.
        • et al.
        Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study.
        PLoS One. 2014; 9: e115060
        • Köhne C.H.
        • Cunningham D.
        • Di Costanzo F.
        • et al.
        Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
        Ann Oncol. 2002; 13: 308-317
        • Kabbinavar F.
        • Irl C.
        • Zurlo A.
        • et al.
        Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
        Oncology. 2008; 75: 215-223
        • Desot E.
        • de Mestier L.
        • Volet J.
        • et al.
        Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: relevance of Köhne’s risk classification.
        Dig Liver Dis. 2013; 45: 330-335
        • Repetto L.
        • Fratino L.
        • Audisio R.A.
        • et al.
        Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study.
        J Clin Oncol. 2002; 20: 494-502